Mark D. Erion

8.0k citations

129 papers · 5.4k indexed · h-index 44

Physiology top 0.2%
- Adenosine and Purinergic Signaling 23
Organic Chemistry top 1%
- Synthesis and Biological Evaluation 11
Molecular Biology top 2%
- Biochemical and Molecular Research 33
- Metabolism, Diabetes, and Cancer 11
Endocrinology, Diabetes and Metabolism top 2%
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment 19
Cancer Research
- Cancer, Hypoxia, and Metabolism 12
Oncology
- Peptidase Inhibition and Analysis 10
Materials Chemistry
- Enzyme Structure and Function 9

Co-authors: M. Rami Reddy Paul D. van Poelje Scott J. Hecker S.E. Ealick Qun Dang Wayne C. Guida Srinivas Rao Kasibhatla Scott Potter
Cited by: Physiology Organic Chemistry Molecular Biology
Journals: Journal of Medicinal Chemistry (25 papers)Journal of the American Chemical Society (12 papers)Biochemistry (7 papers)
Partner nations: United States Switzerland Spain

In The Last Decade

Mark D. Erion

128 papers receiving 5.1k citations

Peers

Countries citing papers authored by Mark D. Erion

Since Specialization

Citations

This map shows the geographic impact of Mark D. Erion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Erion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Erion more than expected).

Fields of papers citing papers by Mark D. Erion

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Erion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Erion. The network helps show where Mark D. Erion may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark D. Erion, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark D. Erion Line = papers co-authored together Mark D. Erion links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The mitochondrial fission protein Drp1 in liver is required to mitigate NASH and prevents the activation of the mitochondrial ISR Molecular Metabolism ·Janos Steffen,Jennifer Ngo,Sheng-Ping Wang,Kevin Jon Williams,Henning F. Kramer,G. C. Ho,Carlos J. Rodríguez,银铎,Chidozie J. Amuzie,Russell Bialecki,Lisa Norquay,Andrea R. Nawrocki,Mark D. Erion,Alessandro Pocai,Orian S. Shirihai,Marc Liesa	2022	32
2	Advances in Binding Free Energies Calculations: QM/MM-Based Free Energy Perturbation Method for Drug Design Current Pharmaceutical Design ·R.S. Rathore,精市熊岡,M. Rami Reddy,Marcio Roberto Henriques Donza,Allam Appa Rao,Mark D. Erion	2013	26
3	Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat Diabetologia ·Mayumi Futamura,Jun Yao,B K Osipov,Raynald Bergeron,Wen Su Xu,Emanuel Zycband,John Woods,Yuhua Zhu,Qing Shao,Hiroko Maruki‐Uchida,Alvin Y. C. Lee,Ronald B. Langdon,Mark D. Erion,Jun‐ichi Eiki,Yun Zhou	2012	33
4	Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents Biopolymers ·Jonathan W. Day,Vasily M. Gelfanov,David L. Smiley,Paul E. Carrington,George J. Eiermann,Gary G. Chicchi,Mark D. Erion,Georg Greifzu,Nancy A. Thornberry,Matthias H. Tschöp,Donald J. Marsh,Ranabir SinhaRoy,Richard D. DiMarchi,Alessandro Pocai	2012	111
5	Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma Cancer Chemotherapy and Pharmacology ·Deidre A. MacKenna,Annika C. Montag,Serge H. Boyer,David L. Linemeyer,Mark D. Erion	2009	6
6	Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist # Hepatology ·Edward E. Cable,Patricia D. Finn,Jeffrey W. Stebbins,Jinzhao Hou,Bruce R. Ito,Paul D. van Poelje,David L. Linemeyer,Mark D. Erion	2008	170
7	Preclinical Pharmacokinetics of a HepDirect Prodrug of a Novel Phosphonate-Containing Thyroid Hormone Receptor Agonist Drug Metabolism and Disposition ·James M. Fujitaki,Edward E. Cable,Bruce R. Ito,Baohong Zhang,Jinzhao Hou,Chun Yang,David A. Bullough,J L Ferrero,Paul D. van Poelje,David L. Linemeyer,Mark D. Erion	2008	27
8	Ab initio quantum mechanics‐based free energy perturbation method for calculating relative solvation free energies Journal of Computational Chemistry ·M. Rami Reddy,U. Chandra Singh,Mark D. Erion	2006	26
9	Free energy calculations in rational drug design M. Rami Reddy,Mark D. Erion	2001	115
10	The structure of human 5′-deoxy-5′-methylthioadenosine phosphorylase at 1.7 Å resolution provides insights into substrate binding and catalysis Structure ·T.C. Appleby,Mark D. Erion,S.E. Ealick	1999	63
11	Suppression of Substance P Biosynthesis in Sensory Neurons of Dorsal Root Ganglion by Prodrug Esters of Potent Peptidylglycine α-Amidating Monooxygenase Inhibitors Journal of Biological Chemistry ·Arco Y. Jeng,Roger A. Fujimoto,Mary Chou,Jenny Tan,Mark D. Erion	1997	14
12	Structure-based design of inhibitors of purine nucleoside phosphorylase Acta Crystallographica Section D Biological Crystallography ·Y.S. Babu,S.E. Ealick,Charles E. Bugg,Mark D. Erion,Wayne C. Guida,John A. Montgomery,محمد مهدی قانع شلمانی	1995	18
13	Modulation of carrageenan-induced hind paw edema by substance P Inflammation ·James P. Gilligan,Cecilia Caseres,Mark D. Erion,Arco Y. Jeng	1994	86
14	Insulinotropic Action of Formycin A Biochemical Medicine and Metabolic Biology ·W J Malaisse,Abdullah Sener,Helen E. Gruber,Mark D. Erion	1994	7
15	N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors Journal of Medicinal Chemistry ·Stéphane De Lombaert,Mark D. Erion,Jenny Tan,Louis Blanchard,کمالالدین خدمتی,Rajesh Ghai,Yumi Sakane,Carol Berry,Angelo J. Trapani	1994	69
16	A radioimmunoassay for measuring α-amidating enzyme activity Analytical Biochemistry ·Arco Y. Jeng,尊代横沢,Cecilia Caseres,Mark D. Erion,James P. Gilligan	1990	10
17	pH- and time-dependent inhibition of rat kidney neutral endoprotease 24.11 by thiorphan and phosphoramidon Life Sciences ·Arco Y. Jeng,Justin Ansell,Mark D. Erion	1989	12
18	Structure-activity relationships for glycine-extended peptides and the α-amidating enzyme derived from medullary thyroid CA-77 cells Archives of Biochemistry and Biophysics ·Paul P. Tamburini,Barry Jones,Angelo P. Consalvo,Stanley D. Young,Cecilia Caseres,James P. Gilligan,Lawrence P. Wennogle,Mark D. Erion,Arco Y. Jeng	1988	26
19	1-Aminocyclopropanephosphonate: time-dependent inactivation of 1-aminocyclopropanecarboxylate deaminase and Bacillus stearothermophilus alanine racemase by slow dissociation behavior Biochemistry ·Mark D. Erion,Christopher T. Walsh	1987	59
20	Chorismate aminations: partial purification of Escherichia coli PABA synthase and mechanistic comparison with anthranilate synthase Biochemistry ·Christopher T. Walsh,Mark D. Erion,Alan E. Walts,Zhengyang Li,Glenn A. Berchtold	1987	27

About Mark D. Erion

Mark D. Erion is a scholar working on Physiology, Molecular Biology, Organic Chemistry, Infectious Diseases and Biochemistry, having authored 129 papers that have together received 5.4k indexed citations. Recurring topics across this work include Biochemical and Molecular Research (33 papers), Adenosine and Purinergic Signaling (23 papers), HIV/AIDS drug development and treatment (19 papers), Cancer, Hypoxia, and Metabolism (12 papers), Metabolism, Diabetes, and Cancer (11 papers), Synthesis and Biological Evaluation (11 papers), Peptidase Inhibition and Analysis (10 papers) and Enzyme Structure and Function (9 papers). The work is most often cited by research in Physiology (613 citations), Organic Chemistry (1.3k citations), Molecular Biology (3.0k citations), Endocrinology, Diabetes and Metabolism (697 citations) and Infectious Diseases (758 citations). Mark D. Erion has collaborated with scholars based in United States, Switzerland and Spain. Frequent co-authors include M. Rami Reddy, Paul D. van Poelje, Scott J. Hecker, S.E. Ealick, Qun Dang, Wayne C. Guida, Srinivas Rao Kasibhatla, Scott Potter, Bheemarao G. Ugarkar and K. Raja Reddy. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of the American Chemical Society, Biochemistry, Journal of Computational Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact